These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38186580)

  • 21. Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.
    Guo B; Wang Y; Liu W; Zhang S
    Clin Transl Oncol; 2023 Feb; 25(2):535-554. PubMed ID: 36255654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive analysis of the prognosis and biological significance for IFIT family in skin cutaneous melanoma.
    Jiang Y; Zhang C; Zhang J; Han D; Shi X
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108344. PubMed ID: 34763233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TREM2 as a Potential Immune-Related Biomarker of Prognosis in Patients with Skin Cutaneous Melanoma Microenvironment.
    Zhu X; Zeng Z; Chen M; Chen X; Hu D; Jiang W; Du M; Chen T; Chen T; Liao W; Zhang C; Qu Y; Pan W
    Dis Markers; 2023; 2023():8101837. PubMed ID: 36741909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction.
    Song J; Yang R; Wei R; Du Y; He P; Liu X
    Mol Med; 2022 May; 28(1):47. PubMed ID: 35508972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The integration of single-cell sequencing, TCGA, and GEO data analysis revealed that PRRT3-AS1 is a biomarker and therapeutic target of SKCM.
    Zhang W; Xie X; Huang Z; Zhong X; Liu Y; Cheong KL; Zhou J; Tang S
    Front Immunol; 2022; 13():919145. PubMed ID: 36211371
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Huang Y; Lin A; Gu T; Hou S; Yao J; Luo P; Zhang J
    Immunotherapy; 2023 Oct; 15(15):1275-1291. PubMed ID: 37584225
    [No Abstract]   [Full Text] [Related]  

  • 27. Development of an IFNγ response-related signature for predicting the survival of cutaneous melanoma.
    Hu B; Wei Q; Li X; Ju M; Wang L; Zhou C; Chen L; Li Z; Wei M; He M; Zhao L
    Cancer Med; 2020 Nov; 9(21):8186-8201. PubMed ID: 32902917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression profile and prognostic values of LSM family in skin cutaneous melanoma.
    Sun X; Zhang J; Xiao C; Ge Z
    BMC Med Genomics; 2022 Nov; 15(1):238. PubMed ID: 36371223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FLG Is a Potential Biomarker of Prognosis and Immunotherapy in Skin Cutaneous Melanoma.
    Wu S; Liang Y; Zang Q; Xing Z; Yin P; Sun R; Dai B
    Appl Bionics Biomech; 2022; 2022():5160748. PubMed ID: 35607429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic and immune-related value of complement C1Q (C1QA, C1QB, and C1QC) in skin cutaneous melanoma.
    Yang H; Che D; Gu Y; Cao D
    Front Genet; 2022; 13():940306. PubMed ID: 36110204
    [No Abstract]   [Full Text] [Related]  

  • 31. FAT10 is a Prognostic Biomarker and Correlated With Immune Infiltrates in Skin Cutaneous Melanoma.
    Wang Y; Zhang H
    Front Mol Biosci; 2022; 9():805887. PubMed ID: 35300113
    [No Abstract]   [Full Text] [Related]  

  • 32. CEBPB is associated with active tumor immune environment and favorable prognosis of metastatic skin cutaneous melanoma.
    Yang J; Xu Y; Xie K; Gao L; Zhong W; Liu X
    Front Immunol; 2022; 13():991797. PubMed ID: 36353635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HOPX is a tumor-suppressive biomarker that corresponds to T cell infiltration in skin cutaneous melanoma.
    He S; Ding Y; Ji Z; Yuan B; Chen J; Ren W
    Cancer Cell Int; 2023 Jun; 23(1):122. PubMed ID: 37344870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
    Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
    Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined signature of G protein-coupled receptors and tumor microenvironment provides a prognostic and therapeutic biomarker for skin cutaneous melanoma.
    Song B; Wang K; Peng Y; Zhu Y; Cui Z; Chen L; Yu Z; Song B
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):18135-18160. PubMed ID: 38006451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unveiling the link between inflammasomes and skin cutaneous melanoma: Insights into expression patterns and immunotherapy response prediction.
    Sheng Y; Liu J; Zhang M; Zheng S
    Math Biosci Eng; 2023 Nov; 20(11):19912-19928. PubMed ID: 38052629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Downregulation of the paired box gene 3 inhibits the progression of skin cutaneous melanoma by inhibiting c-MET tyrosine kinase : PAX3 downregulation inhibits melanoma progression.
    Zhang K; Yu C; Tian R; Zhang W; Tang S; Wang G
    Mol Biol Rep; 2022 Oct; 49(10):9137-9145. PubMed ID: 36057879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prognostic gene CRABP2 affects drug sensitivity by regulating docetaxel-induced apoptosis in breast invasive carcinoma: A pan-cancer analysis.
    Zeng S; Xu Z; Liang Q; Thakur A; Liu Y; Zhou S; Yan Y
    Chem Biol Interact; 2023 Mar; 373():110372. PubMed ID: 36736488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A CD8
    Sun S; Zhi Z; Su Y; Sun J; Li Q
    Front Immunol; 2022; 13():1039565. PubMed ID: 36341357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying biomarkers associated with immunotherapy response in melanoma by multi-omics analysis.
    He Y; Wang X
    Comput Biol Med; 2023 Dec; 167():107591. PubMed ID: 37875043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.